Sotera Health (NASDAQ:SHC) Rating Increased to Moderate Buy at Royal Bank Of Canada

Sotera Health (NASDAQ:SHC) was upgraded by research analysts at Royal Bank Of Canada to a “moderate buy” rating in a research note issued on Thursday,Zacks.com reports.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sotera Health in a research note on Monday, December 29th. BMO Capital Markets began coverage on shares of Sotera Health in a report on Thursday, November 13th. They set an “outperform” rating and a $19.00 price objective on the stock. Wells Fargo & Company lowered shares of Sotera Health to an “overweight” rating in a research note on Thursday. Zacks Research raised Sotera Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Finally, Barclays boosted their price target on Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Sotera Health presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Sotera Health Stock Performance

SHC stock opened at $19.21 on Thursday. Sotera Health has a 1-year low of $9.53 and a 1-year high of $19.85. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04. The firm has a market cap of $5.46 billion, a PE ratio of 101.09 and a beta of 1.82. The business’s 50-day moving average price is $16.97 and its two-hundred day moving average price is $15.32.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. Sotera Health had a return on equity of 43.69% and a net margin of 4.82%.The company had revenue of $311.31 million during the quarter, compared to the consensus estimate of $303.63 million. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. As a group, research analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 6,480,000 shares of Sotera Health stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $105,818,400.00. Following the sale, the director owned 22,735,301 shares of the company’s stock, valued at approximately $371,267,465.33. The trade was a 22.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pincus & Co. Warburg sold 9,720,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $158,727,600.00. Following the sale, the director owned 34,102,952 shares in the company, valued at $556,901,206.16. The trade was a 22.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 29,384,104 shares of company stock valued at $471,824,511 in the last three months. 47.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC raised its stake in shares of Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock worth $332,000 after purchasing an additional 2,845 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Sotera Health by 14.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after buying an additional 43,471 shares during the last quarter. Acadian Asset Management LLC raised its position in Sotera Health by 125.5% during the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares in the last quarter. Strs Ohio acquired a new stake in Sotera Health in the first quarter valued at $1,003,000. Finally, Parallel Advisors LLC lifted its stake in Sotera Health by 124.0% in the second quarter. Parallel Advisors LLC now owns 3,340 shares of the company’s stock valued at $37,000 after acquiring an additional 1,849 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.